Multiple myeloma (MM) is a devastating plasma cell cancer. Median survival is currently ~3 years but some patients live longer than 10 years, underscoring the patient-to-patient variability of this disease. A valuable tool in better understanding the biology and treatment of disease has been the establishment and study of continuously growing human myeloma cell lines (HMCLs). However, currently existing HMCLs only provide a model system for one subgroup of MM disease (referred to as ‘nonhyperdiploid’). The overall goal of this proposal is therefore to establish new HMCLs from patients with all types of myeloma, particularly those referred to as hyperdiploid.